Kodiak Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Kodiak Sciences şirketinin toplam hissedar öz sermayesi $214.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $401.6M ve $187.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$219.23m
Eşitlik	US$214.51m
Toplam yükümlülükler	US$187.07m
Toplam varlıklar	US$401.58m

Son finansal sağlık güncellemeleri

Recent updates

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Aug 02

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Apr 17

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Dec 29

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Sep 09

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

May 26

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Jan 04

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Sep 25

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Aug 25

Kodiak Sciences FQ1 2022 Earnings Preview

Aug 07

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

May 18

Kodiak Sciences: Potential For Comeback After Trial Setback

May 17

Kodiak Sciences: KSI-301 Disappoints

Feb 25

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

Feb 15

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Jan 24

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Oct 11

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Jul 19

Kodiak Sciences EPS in-line

May 10

Kodiak Sciences hits the capital raise button; shares dip after hours

Nov 16

Kodiak Sciences EPS misses by $0.12

Nov 09

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: KOD 'nin kısa vadeli varlıkları ( $224.6M ) kısa vadeli yükümlülüklerini ( $21.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: KOD şirketinin kısa vadeli varlıkları ( $224.6M ) uzun vadeli yükümlülüklerini ( $165.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: KOD borçsuzdur.

Borcun Azaltılması: KOD un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: KOD şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: KOD serbest nakit akışı her yıl % 30.5 1.1 yıl yetecek nakit akışına sahip olacaktır.

Kodiak Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Recent updates

Kodiak Sciences Inc. Announces Executive Appointments

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New major risk - Share price stability

Kodiak Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

Price target decreased by 40% to US$2.63

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Kokak Sciences Inc. Announces Top-Line, One-Year Results for Its ABC Platform Based Investigational Therapy Tarcocimab Tedromer 5 Mg from the Pivotal Beacon Study

Jason Ehrlich, M.D., Ph.D., Informs Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Jason Ehrlich, M.D., Ph.D., Informes Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

No longer forecast to breakeven

Forecast to breakeven in 2025

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

New major risk - Share price stability

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

Insufficient new directors

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Kodiak Sciences Reports Positive Topline Results from Beacon Phase 3 Study of Tarcocimab Tedromer (Ksi-301) in Patients with Retinal Vein Occlusion

Kodiak Sciences FQ1 2022 Earnings Preview

Kodiak Sciences Inc. Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Insider notifies of intention to sell stock

Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell 2000 Growth Index

Price target decreased to US$12.60

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

Kodiak Sciences: Potential For Comeback After Trial Setback

Co-Founder recently sold US$12m worth of stock

Kodiak Sciences: KSI-301 Disappoints

Kodiak Sciences Inc. Announces Top-Line Results from Its Initial Phase 2B/3 Study of KSI-301 in Patients with Neovascular Age-Related Macular Degeneration

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

Insider notifies of intention to sell stock

Kodiak Sciences Inc. Completes Enrollment in Gleam and Glimmer Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Insider notifies of intention to sell stock

Price target decreased to US$117

Insider notifies of intention to sell stock

Insider exercised options and sold US$376k worth of stock

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Kodiak Sciences Inc. Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Senior VP notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider exercised options and sold US$705k worth of stock

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Kodiak Sciences EPS in-line

Kodiak Sciences Inc. Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1B Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences hits the capital raise button; shares dip after hours

Kodiak Sciences Inc. to Report Q3, 2020 Results on Nov 09, 2020

Kodiak Sciences EPS misses by $0.12

Kodiak Sciences Inc. Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell Microcap Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço